Anixa Biosciences announces treatment of third patient in CAR-T trial

Anixa Biosciences announced that, in partnership with Moffitt Cancer Center, it has commenced treatment of the third patient in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell, CAR-T, therapy for ovarian cancer. The study, which is being conducted at Moffitt Cancer Center, is a dose-escalation Phase 1 trial to evaluate the therapy’s safety; determine the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor, FSHR; and preliminarily assess clinical activity. The third patient received the same dose of engineered T-cells as the first and second patients in the trial. Assuming safety is validated in the third patient, as was the case for the first two patients, Anixa expects to begin treatment of the second cohort in the fourth quarter of 2023. “Though enrollment of patients in this trial has been slow, which is common for clinical studies of this type, we are pleased to have completed the first cohort,” stated, Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. “Assuming there are no safety issues with this third patient, we look forward to advancing to the next higher dose cohort.”